SCHEMBL2221283

SCHEMBL2221283

CC1=NN(c2cccc(C(=O)O)c2)C(=O)C1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 9/20 0.71
MAPT P10636 8/20 0.71
MEN1 O00255 7/20 0.71
GAA P10253 5/20 0.71
L3MBTL1 Q9Y468 3/20 0.71
KDM4E B2RXH2 5/20 0.65
ALDH1A1 P00352 7/20 0.65
TDP1 Q9NUW8 5/20 0.65
CYP1A2 P05177 2/20 0.65
CYP3A4 P08684 2/20 0.65
CHRM2 P08172 1/20 0.65
CHRM1 P11229 1/20 0.65
TSHR P16473 1/20 0.65
PTGS1 P23219 1/20 0.65
DRD3 P35462 1/20 0.65
SMN1; SMN2 Q16637 1/20 0.65
APP P05067 5/20 0.60
POLB P06746 5/20 0.60
THRB P10828 1/20 0.60
CASP6 P55212 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2854377 0.89 MAPT (0.65) KMT2AMAPTMEN1GAAL3MBTL1
SCHEMBL9854205 0.85 MAPT (0.58) KMT2AMAPTMEN1GAAL3MBTL1
SCHEMBL2228950 0.85 MAPT (0.60) KMT2AMAPTMEN1GAAL3MBTL1
SCHEMBL12756285 0.85 MAPT (0.81) KMT2AMAPTMEN1GAAL3MBTL1
SCHEMBL13187322 0.83 KMT2A (1.00) KMT2AMAPTMEN1GAAL3MBTL1
SCHEMBL19644103 0.83 GAA (0.58) KMT2AMAPTMEN1GAAL3MBTL1
SCHEMBL29389131 0.83 GAA (0.58) KMT2AMAPTMEN1GAAL3MBTL1
SCHEMBL5468055 0.82 KMT2A (0.66) KMT2AMAPTMEN1GAAL3MBTL1
SCHEMBL643536 0.82 POLB (0.75) KMT2AMAPTMEN1GAAL3MBTL1
SCHEMBL5476546 0.82 KMT2A (0.69) KMT2AMAPTMEN1GAAL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3684354-B1 XPA INHIBITOR COMPOUNDS AND THEIR USE UNIV INDIANA RES & TECH CORP (US) 2023-11-15 EP disclosed
US-20220089577-A1 KU INHIBITORS AND THEIR USE UNIV INDIANA RES & TECH CORP (US) 2022-03-24 US disclosed
EP-3463371-B1 KU INHIBITORS AND THEIR USE UNIV INDIANA RES & TECH CORP (US) 2022-02-23 EP disclosed
US-11207296-B2 XPA inhibitor compounds and their use INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2021-12-28 US disclosed
US-20200308154-A1 KU INHIBITORS AND THEIR USE INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION 2020-10-01 US disclosed
EP-3684354-A1 XPA INHIBITOR COMPOUNDS AND THEIR USE Indiana University Research and Technology Corporation (US) 2020-07-29 EP disclosed
US-20200222367-A1 XPA INHIBITOR COMPOUNDS AND THEIR USE INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION 2020-07-16 US disclosed
EP-3463371-A1 KU INHIBITORS AND THEIR USE Indiana University Research & Technology Corporation (US) 2019-04-10 EP disclosed
WO-2019060260-A1 XPA INHIBITOR COMPOUNDS AND THEIR USE INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2019-03-28 WO disclosed
WO-2017205503-A1 KU INHIBITORS AND THEIR USE INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2017-11-30 WO disclosed
US-7285663-B2 β-Isoindigo coloring agent CLARIANT PRODUKTE (DEUTSCHLAND) GMBH (DE) 2007-10-23 US disclosed
EP-1223944-B1 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORP (US) 2007-01-03 EP disclosed
EP-1587877-B1 BETA-ISOINDIGO COLORING AGENT CLARIANT PRODUKTE DEUTSCHLAND (DE) 2006-06-14 EP disclosed
US-20060041034-A1 B-isoindigo coloring agent CLARIANT PRODUKTE (DEUTSCHLAND) GMBH (DE) 2006-02-23 US disclosed
EP-1587877-A1 BETA-ISOINDIGO COLORING AGENT Clariant GmbH (DE) 2005-10-26 EP disclosed
WO-2004065490-A1 ss-ISOINDIGO COLORING AGENT CLARIANT GMBH (DE) 2004-08-05 WO disclosed
US-6552008-B1 Administering effective amount of a selected azo-pyrazole derivative for therapy of thrombocytopenia SMITHKLINE BEECHAM CORPORATION 2003-04-22 US disclosed
EP-1223944-A4 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORP (US) 2002-10-30 EP disclosed
EP-1223944-A1 THROMBOPOIETIN MIMETICS SmithKline Beecham Corporation (US) 2002-07-24 EP disclosed
WO-2001021180-A1 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION (US) 2001-03-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220089577-A1 KU INHIBITORS AND THEIR USE ZFR, XRCC6, ZFX KMT2A 317/4885MAPT 3583/4885MEN1 2172/4885
US-20200222367-A1 XPA INHIBITOR COMPOUNDS AND THEIR USE XPOT, XPA, ERCC4 KMT2A 1736/4885MAPT 3599/4885MEN1 884/4885
US-11207296-B2 XPA inhibitor compounds and their use XPOT, XPA, ERCC4 KMT2A 1736/4885MAPT 3599/4885MEN1 884/4885
US-20200308154-A1 KU INHIBITORS AND THEIR USE ZFR, XRCC6, ZFX KMT2A 317/4885MAPT 3583/4885MEN1 2172/4885
US-20060041034-A1 B-isoindigo coloring agent IPO11, BBOX1, IPO4 KMT2A 3242/4885MAPT 2428/4885MEN1 1994/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.